Mammography

In this volume, the topics are constructed from a variety of contents: the bases of mammography systems, optimization of screening mammography with reference to evidence-based research, new technologies of image acquisition and its surrounding systems, and case reports with reference to up-to-date multimodality images of breast cancer. Mammography has been lagged in the transition to digital imaging systems because of the necessity of high resolution for diagnosis. However, in the past ten years, technical improvement has resolved the difficulties and boosted new diagnostic systems. We hope that the reader will learn the essentials of mammography and will be forward-looking for the new technologies. We want to express our sincere gratitude and appreciation?to all the co-authors who have contributed their work to this volume

Recall Rates in Screening Mammography: Variability in Performance and Decisions

Having a high recall rate may increase the probability of cancer being detected earlier, however it also has been related to increased false positive decisions, causing significant psychological and economical costs for both screened women and the mammography screening service. Therefore, the purpose of this thesis is to explore the impact of various recall rates on breast radiologists’ performance in a laboratory setting. Methods This study was designed to encompass two aspects 1) the effect of setting varying recall rates on the performance of breast radiologists in screening mammography 2) types of mammographic appearances of breast cancer are more likely to be missed at different recall rates. Five Australian breast radiologists were recruited to read one single test set of 200 mammographic cases (180 normal and 20 abnormal cases) over three different recall rate conditions: free recall, 15% and 10%. These radiologists were tasked with marking the location of suspicious lesions and providing a confidence. Results A significant decrease in radiologists’ performance was observed when reading at lower recall rates, with lower sensitivity (P=0.002), case location sensitivity (P=0.002) and ROC AUC (P=0.003). Reading at a lower recall rate had a significant increase in specificity (P=0.002). The second study of this thesis showed that breast radiologists demonstrated lower sensitivity and receiver ROC AUC for non-specific density (NSD) (P=0.04 and P=0.03 respectively) and mixed features (P=0.01 and P=0.04 respectively) when reading at 15% and 10% recall rates. No significant change was observed on cancer characterized with stellate masses (P=0.18 and P=0.54 respectively) and architectural distortion (P=1.00 and P=0.37 respectively). Conclusion Reducing the number of recalled cases to 10% significantly reduced breast radiologists’ performance. Stellate masses were likely to be recalled (90.0%) while NSDs were likely to be missed (45.6%) at reduced recall rates

Risk assessment and prevention of breast cancer

One woman in eight develops breast cancer during her lifetime in the Western world. Measures are warranted to reduce mortality and to prevent breast cancer. Mammography screening reduces mortality by early detection. However, approximately one fourth of the women who develop breast cancer are diagnosed within two years after a negative screen. There is a need to identify the short-term risk of these women to better guide clinical followup. Another drawback of mammography screening is that it focuses on early detection only and not on breast cancer prevention. Today, it is known that women attending screening can be stratified into high and low risk of breast cancer. Women at high risk could be offered preventive measures such as low-dose tamoxifen to reduce breast cancer incidence. Women at low risk do not benefit from screening and could be offered less frequent screening. In study I, we developed and validated the mammographic density measurement tool STRATUS to enable mammogram resources at hospitals for large scale epidemiological studies on risk, masking, and therapy response in relation to breast cancer. STRATUS showed similar measurement results on different types of mammograms at different hospitals. Longitudinal studies on mammographic density could also be analysed more accurate with less nonbiological variability. In study II, we developed and validated a short-term risk model based on mammographic features (mammographic density, microcalcifications, masses) and differences in occurrences of mammographic features between left and right breasts. The model could optionally be expanded with lifestyle factors, family history of breast cancer, and genetic determinants. Based on the results, we showed that among women with a negative mammography screen, the short-term risk tool was suitable to identify women that developed breast cancer before or at next screening. We also showed that traditional long-term risk models were less suitable to identify the women who in a short time-period after risk assessment were diagnosed with breast cancer. In study III, we performed a phase II trial to identify the lowest dose of tamoxifen that could reduce mammographic density, an early marker for reduced breast cancer risk, to the same extent as standard 20 mg dose but cause less side-effects. We identified 2.5 mg tamoxifen to be non-inferior for reducing mammographic density. The women who used 2.5 mg tamoxifen also reported approximately 50% less severe vasomotor side-effects. In study IV, we investigated the use of low-dose tamoxifen for an additional clinical use case to increase screening sensitivity through its effect on reducing mammographic density. It was shown that 24% of the interval cancers have a potential to be detected at prior screen. In conclusion, tools were developed for assessing mammographic density and breast cancer risk. In addition, two low-dose tamoxifen concepts were developed for breast cancer prevention and improved screening sensitivity. Clinical prospective validation is further needed for the risk assessment tool and the low-dose tamoxifen concepts for the use in breast cancer prevention and for reducing breast cancer mortality